< 返回主頁

Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial

by | 5月 22, 2020 | 流感、冠病防治硏究資料

類型: 連結
作者: Feng-Cai Zhu et al.
出處: The Lancet
連結: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31208-3/fulltext